FDA Drug Shortage Alert: Hydromorphone Hydrochloride Injection — Demand-Driven Shortage

The FDA declared hydromorphone hydrochloride injection in current shortage status on January 15, 2025, driven by increased demand that has exceeded manufacturing capacity. Wholesale drug distributors now face allocation protocols from primary manufacturers and must adapt procurement strategies for a Schedule II controlled substance under simultaneous DEA quota restrictions and DSCSA traceability requirements.

Regulatory Framework

Hydromorphone hydrochloride injection is a Schedule II controlled substance under the Controlled Substances Act (21 U.S.C. § 812). DEA sets annual manufacturing quotas for all Schedule II opioids under 21 CFR Part 1303. When a Schedule II drug enters shortage, DEA may adjust quotas, but manufacturers cannot exceed authorized production limits without quota amendments.

The FDA tracks drug shortages under Section 506C of the FD&C Act and publishes shortage data through the FDA Drug Shortages Database. The agency defines a shortage as "a period of time when the demand or projected demand for a drug exceeds its supply." For controlled substances, shortages trigger allocation decisions by manufacturers, creating downstream supply chain management challenges for wholesale distributors.

Under the DSCSA (Drug Supply Chain Security Act, enacted 2013), wholesale distributors must maintain transaction history, transaction information, and transaction statements for all prescription drugs, including controlled substances. Enhanced drug distribution security requirements went into full enforcement on November 27, 2024. Hydromorphone injection shortage conditions do not exempt distributors from DSCSA traceability obligations.

Shortage Details

FDA's January 15, 2025 alert identifies increased demand as the primary driver. Three manufacturers supply the U.S. market: Hikma Pharmaceuticals, Fresenius Kabi, and Pfizer (via Hospira). All three report current inventory, but production capacity cannot meet elevated ordering volumes.

Affected presentations:

• Hydromorphone HCl 1 mg/mL, 2 mg/mL, and 10 mg/mL injectable solutions
• Single-dose vials (1 mL, 2 mL, 5 mL, 20 mL, 50 mL)
• Pre-filled syringes (select strengths)

Manufacturer allocation status:

• Hikma: Allocation in place as of January 10, 2025. Orders reduced to 70% of historical volume.
• Fresenius Kabi: Allocation expected by January 31, 2025. No public allocation percentage disclosed.
• Pfizer/Hospira: Current supply available but declining weekly. No formal allocation announced.

The FDA has not issued temporary importation authorization for foreign-manufactured hydromorphone, meaning distributors cannot source product from non-U.S.-approved manufacturers as a shortage mitigation strategy.

Distributor Operational Impact

Controlled Substance Documentation

Wholesale drug distributors handling Schedule II substances must maintain DEA Form 222 or CSOS (Controlled Substances Ordering System) records for all hydromorphone transactions. Shortage conditions do not alter this requirement. Distributors operating under allocation must document allocation tiers and prioritization criteria for audit purposes.

State-specific controlled substance reporting varies. California requires CURES (Controlled Substance Utilization Review and Evaluation System) reporting for Schedule II-V substances. New York mandates I-STOP (Internet System for Tracking Over-Prescribing) reporting. Distributors serving multi-state customer bases must maintain compliance with each jurisdiction's reporting obligations during allocation periods.

Procurement Strategy Adjustments

Distributors facing manufacturer allocation must adjust purchasing patterns:

• Order consolidation: Smaller, more frequent orders may trigger allocation penalties. Distributors should verify manufacturer allocation rules before changing order cadence.
• Secondary market sourcing: Gray market hydromorphone purchases carry heightened DSCSA verification burdens. Distributors must verify all transaction history back to the manufacturer for secondary-sourced product.
• Customer allocation: Distributors implementing their own downstream allocation must document allocation methodology for state board of pharmacy audits.

Cold Chain Implications

Hydromorphone injection does not require refrigeration (store at 20-25°C/68-77°F), but shortage-driven procurement from secondary sources increases risk of storage excursion exposure. Distributors should verify temperature monitoring data for any non-primary-source product.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these, 1,234 entities hold active FDA registration — a prerequisite for lawful distribution of any FDA-regulated drug, including hydromorphone injection. The 41 entities without verified FDA registration should not be sourcing partners during shortage conditions, when procurement scrutiny intensifies.

The average compliance score across all tracked entities is 51/100, placing the industry in the "Fair" tier. This reflects incomplete public data availability rather than universal non-compliance, but the distribution is telling: 28 entities score in the "Excellent" range (76-100 points), while 47 entities score "Poor" or "Minimal" (0-25 points). During allocation-driven shortages, procurement teams should prioritize distributors in the upper score brackets where compliance signals are most verifiable.

Only 63 entities in the directory hold NABP accreditation (formerly VAWD). NABP-accredited distributors undergo third-party verification of DSCSA compliance, controlled substance handling procedures, and state licensure status — all critical during Schedule II shortage management. For hydromorphone procurement, NABP accreditation provides an independent compliance signal beyond self-certification.

73 entities in the directory have at least one FDA recall on record. Recalls are not disqualifying — many reflect voluntary actions or administrative corrections — but procurement during shortage conditions warrants elevated due diligence. Secondary-market sourcing from entities with recent recalls increases transaction verification burden under DSCSA.

Practical Guidance for Shortage Response

For QA/Regulatory Managers:

• Verify existing distributor partners using the ColdChainCheck directory. Filter by FDA registration status and NABP accreditation. If your current hydromorphone supplier lacks verified FDA registration, document the gap and escalate to procurement.
• Document allocation methodology if implementing downstream customer allocation. State boards of pharmacy may audit allocation decisions during controlled substance shortages. Maintain records showing allocation was based on historical purchasing patterns, not favoritism or price.
• Prepare enhanced DSCSA verification workflows for secondary-market purchases. If sourcing hydromorphone from non-primary distributors, verify transaction history back to the manufacturer. ColdChainCheck's compliance score breakdown shows whether a potential supplier has FDA enforcement actions or recall history that would warrant heightened scrutiny.
• Monitor DEA quota updates. If DEA increases hydromorphone manufacturing quotas, manufacturer allocation may ease. Cross-reference DEA quota adjustments (published quarterly at deadiversion.usdoj.gov) with FDA shortage database updates.

For Procurement Teams:

• Use ColdChainCheck's state licensure data to confirm multi-state distributors hold active wholesale drug licenses in your operating jurisdictions. A distributor licensed in 42 states may not be licensed in your state — verify before placing shortage-driven orders.

ColdChainCheck does not track real-time product availability or allocation percentages — this data is proprietary to manufacturers. The directory provides compliance signals to inform which distributors are qualified partners during shortage procurement, not what inventory they hold.

For ongoing shortage monitoring, see ColdChainCheck's DSCSA Compliance Guide and State Licensure Requirements by Jurisdiction.

Disclaimer: This article is for informational purposes only and does not constitute legal, regulatory, or compliance advice. ColdChainCheck data is based on publicly available sources and may not reflect real-time changes. Verify all compliance information with the relevant regulatory authority or legal counsel before making procurement decisions.

Update: Remifentanil Shortage 2025 | FDA Alert for Distributors — ColdChainCheck

April 4, 2026

FDA Reports Remifentanil Hydrochloride Injection Shortage: What Wholesale Drug Distributors Need to Know

The FDA added remifentanil hydrochloride injection to the agency's drug shortage database on January 14, 2025, designating the shortage as ongoing with limited availability. Remifentanil is a Schedule II controlled substance and potent ultra-short-acting opioid used during anesthesia and in critical care settings. The shortage creates immediate allocation challenges for wholesale drug distributors managing controlled substance inventories and regulatory reporting obligations under both the Controlled Substances Act and state-level distribution requirements.

Regulatory Framework for Drug Shortage Response

Under 21 U.S.C. § 356c, manufacturers must notify the FDA at least six months before discontinuing production of a medically necessary drug. The FDA Drug Shortages Program, operated by the Center for Drug Evaluation and Research (CDER), maintains a public database of drugs in shortage and works with manufacturers to prevent or mitigate supply disruptions.

Wholesale drug distributors face distinct compliance obligations when distributing drugs in shortage status. The Drug Supply Chain Security Act (DSCSA) requires transaction information, transaction history, and transaction statements for all prescription drug distributions — requirements that remain in effect during shortages. State boards of pharmacy in multiple jurisdictions also impose reporting requirements when distributors cannot fulfill orders for critical medications, particularly controlled substances in Schedule II.

DEA regulations under 21 CFR Part 1301-1308 govern the distribution of Schedule II controlled substances. Distributors must maintain DEA registration, file biennial inventory reports, and document every distribution transaction. When a Schedule II drug enters shortage, distributors face increased scrutiny on allocation practices to ensure compliance with the Controlled Substances Act's prohibition on diversion.

Remifentanil Shortage Details

As of January 14, 2025, the FDA reports remifentanil hydrochloride injection as experiencing ongoing shortage with limited availability across multiple presentations. The drug is manufactured by a small number of suppliers, and the agency has not disclosed the specific cause of the current supply disruption.

Remifentanil is classified as medically necessary by the FDA due to its unique pharmacological profile: rapid onset (1 minute) and ultra-short duration (3-10 minutes) make it essential for specific surgical procedures and mechanically ventilated ICU patients. No therapeutically equivalent alternative provides the same combination of potency and rapid offset. Anesthesiologists rely on remifentanil for controlled hypotension during neurosurgery, cardiac surgery, and procedures requiring immediate reversal of opioid effects.

The FDA has not issued formal allocation guidance for remifentanil, but the agency typically prioritizes distribution to hospitals performing critical surgeries when shortages involve single-source anesthesia medications.

Distributor Compliance and Allocation Obligations

Wholesale drug distributors managing remifentanil inventory must document allocation decisions when supply cannot meet demand. While the DSCSA does not prescribe specific allocation methodologies, the act requires distributors to maintain transaction records demonstrating legitimate distribution channels. State boards of pharmacy in California, New York, Texas, and Ohio have issued guidance requiring distributors to report anticipated shortages of critical medications to the board within specified timeframes — typically 72 hours of receiving manufacturer notification.

Controlled substance allocation raises additional DEA compliance considerations. Distributors must ensure allocation practices do not create suspicious order patterns under 21 CFR § 1301.74(b), which requires registrants to design and operate a system to detect and report suspicious orders. During shortages, changes in ordering patterns — such as customers requesting maximum allowable quantities or switching to alternative suppliers — may trigger automated monitoring systems.

Fair and equitable distribution principles apply during shortages, but the DSCSA and CSA do not define specific allocation formulas. Distributors commonly use pro-rata allocation based on historical purchase volume, geographic distribution to ensure regional access, or priority allocation to entities providing emergency or critical care services. The selected methodology must be documented and applied consistently to withstand regulatory scrutiny during inspections.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors tracked in the ColdChainCheck directory, 1,234 hold active FDA registration — a baseline requirement for distributing prescription drugs including controlled substances like remifentanil. However, FDA registration alone does not indicate DEA licensure to distribute Schedule II controlled substances. ColdChainCheck does not yet include DEA registration data in compliance scoring, meaning entities handling remifentanil require additional verification beyond the directory's current scope.

The average compliance score across tracked entities is 51/100, placing the majority of distributors in the "Fair" compliance tier. This score reflects verified state licensure, NABP accreditation status, and FDA registration — but not controlled substance distribution authority. Only 63 entities hold NABP accreditation (formerly VAWD), representing less than 5% of the directory. NABP-accredited distributors demonstrate additional third-party verification of their quality systems and are more likely to have documented allocation policies required during drug shortages.

73 entities in the directory have at least one FDA enforcement action or recall on record. During shortage conditions, distributors with prior compliance failures face heightened scrutiny on allocation practices and transaction documentation. State boards of pharmacy frequently cross-reference shortage reporting against entities' compliance history when investigating allocation complaints.

Practical Guidance for QA and Procurement Teams

• Verify DEA registration independently: Use the DEA's Diversion Control Division lookup tool to confirm your distributor holds active DEA registration for Schedule II controlled substances. ColdChainCheck's FDA registration data does not include controlled substance authority.

• Review allocation documentation requirements: If your distributor notifies you of remifentanil allocation or backorder, request written documentation of their allocation methodology. Maintain this documentation as part of your trading partner qualification records under DSCSA requirements.

• Check state-specific shortage reporting: Distributors in California, New York, Texas, and Ohio must report anticipated shortages to state boards of pharmacy. Cross-reference your distributor's compliance posture using the ColdChainCheck directory to assess their licensure status in relevant jurisdictions.

• Monitor FDA updates: The FDA Drug Shortages Database updates shortage status weekly. ColdChainCheck tracks regulatory developments affecting wholesale distributors in the compliance guides section, including FDA enforcement trends and state board actions related to controlled substance distribution.

Disclaimer: This article presents publicly available regulatory information for informational purposes only. It does not constitute legal or compliance advice. Verify all regulatory requirements with the relevant state board of pharmacy, FDA, and DEA for your specific circumstances.